Bertrand Allard
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Assessing the Efficacy of Immune Checkpoint Inhibitors in Preclinical Tumor Models.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: December 31, 2022
Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma.
Journal: Cell reports. Medicine
Published: December 01, 2022
The CD73 immune checkpoint promotes tumor cell metabolic fitness.
Journal: eLife
Published: October 26, 2022
CD73 Inhibits cGAS-STING and Cooperates with CD39 to Promote Pancreatic Cancer.
Journal: Cancer immunology research
Published: April 04, 2022
1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer.
Journal: Science advances
Published: July 31, 2020
Publisher Correction: The adenosine pathway in immuno-oncology.
Journal: Nature reviews. Clinical oncology
Published: July 19, 2020
The adenosine pathway in immuno-oncology.
Journal: Nature reviews. Clinical oncology
Published: April 29, 2020
On the mechanism of anti-CD39 immune checkpoint therapy.
Journal: Journal for immunotherapy of cancer
Published: December 28, 2019
Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assays.
Journal: Methods in enzymology
Published: November 16, 2019
Targeting the adenosine pathway for cancer immunotherapy.
Journal: Seminars in immunology
Published: March 27, 2019
Adenosine A2a receptor promotes lymphangiogenesis and lymph node metastasis.
Journal: Oncoimmunology
Published: November 13, 2018
Last Updated: 09/26/2026